tiprankstipranks
Trending News
More News >
Nephros Inc (NEPH)
NASDAQ:NEPH

Nephros (NEPH) Price & Analysis

Compare
90 Followers

NEPH Stock Chart & Stats

$5.01
<$0.01(0.48%)
At close: 4:00 PM EST
$5.01
<$0.01(0.48%)

Bulls Say, Bears Say

Bulls Say
Sustained ProfitabilityAchieving five consecutive profitable quarters demonstrates the business model can generate consistent earnings, reducing reliance on external financing. Sustained profitability improves capacity to reinvest in R&D, scale sales, and absorb cyclical downturns, materially strengthening long-term resilience.
Strong Cash Generation & Low LeveragePositive operating and free cash flow combined with minimal debt provide financial flexibility to fund growth initiatives, weather demand volatility, and negotiate partnerships. This cash strength supports durable operations and reduces refinancing risk over the medium term.
Product & Market Expansion (PFAS, Medica Deal)Strategic product innovation (PFAS removal) and an exclusive licensing deal with Medica broaden addressable markets beyond dialysis into municipalities and labs. These structural moves diversify revenue streams and create durable channels for recurring consumable sales and scale.
Bears Say
Historical Earnings VolatilityAlthough recent results improved, the company has prior multi-year losses and uneven cash flow. That track record implies execution and demand sensitivity risks remain, meaning future profitability could reverse if growth slows or one-time benefits fade.
Relatively Thin MarginsModest operating and net margins limit the firm's ability to absorb cost inflation, tariffs, or competitive pricing pressure. Lower margin buffers restrict reinvestment capacity and make earnings more sensitive to cost swings, raising execution risk over 2–6 months.
Rising Opex And Tariff PressureIncreasing R&D and SG&A, plus tariff-driven inventory handling costs, compress margins and raise the breakeven required for profitable growth. If operating expenses remain elevated or tariffs persist, cash generation and margin sustainability could be impaired long term.

Nephros News

NEPH FAQ

What was Nephros Inc’s price range in the past 12 months?
Nephros Inc lowest stock price was $1.39 and its highest was $6.42 in the past 12 months.
    What is Nephros Inc’s market cap?
    Nephros Inc’s market cap is $41.55M.
      When is Nephros Inc’s upcoming earnings report date?
      Nephros Inc’s upcoming earnings report date is Mar 05, 2026 which is in 3 days.
        How were Nephros Inc’s earnings last quarter?
        Nephros Inc released its earnings results on Nov 06, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.05.
          Is Nephros Inc overvalued?
          According to Wall Street analysts Nephros Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Nephros Inc pay dividends?
            Nephros Inc does not currently pay dividends.
            What is Nephros Inc’s EPS estimate?
            Nephros Inc’s EPS estimate is 0.01.
              How many shares outstanding does Nephros Inc have?
              Nephros Inc has 10,626,683 shares outstanding.
                What happened to Nephros Inc’s price movement after its last earnings report?
                Nephros Inc reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went down -11.538%.
                  Which hedge fund is a major shareholder of Nephros Inc?
                  Currently, no hedge funds are holding shares in NEPH
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Nephros Stock Smart Score

                    7
                    Neutral
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10

                    Technicals

                    SMA
                    Positive
                    20 days / 200 days
                    Momentum
                    226.00%
                    12-Months-Change

                    Fundamentals

                    Return on Equity
                    16.29%
                    Trailing 12-Months
                    Asset Growth
                    10.30%
                    Trailing 12-Months

                    Company Description

                    Nephros Inc

                    Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

                    Nephros (NEPH) Earnings & Revenues

                    NEPH Earnings Call

                    Q3 2025
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The earnings call reflects a strong performance for Nephros, highlighted by substantial revenue growth, sustained profitability, and strategic innovation in new markets. Despite challenges with increased operating expenses and tariff impacts, the company's robust cash flow and expanding customer base indicate a positive outlook.View all NEPH earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Harvard Bioscience
                    Retractable Technologies
                    Milestone Scientific
                    Femasys

                    Ownership Overview

                    2.41%2.85%36.74%56.13%
                    36.74% Other Institutional Investors
                    56.13% Public Companies and
                    Individual Investors

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks